Traws Pharma GAAP EPS of -$0.53 beats by $0.03, revenue of $0M
Source: SeekingAlpha
2026-05-15 07:03:10 ET
More on Traws Pharma
- Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
- Traws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027
- Traws Pharma prices $60M PIPE financing deal to fund UK flu trial
- Seeking Alpha’s Quant Rating on Traws Pharma
- Historical earnings data for Traws Pharma
Read the full article on Seeking Alpha
For further details see:
Traws Pharma GAAP EPS of -$0.53 beats by $0.03, revenue of $0M
Traws Pharma Inc.
NASDAQ: TRAW
TRAW Trading
8.13% G/L:
$1.6869 Last:
571,383 Volume:
$1.55 Open:
TRAW Latest News
May 15, 2026 07:00:00 am
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 08, 2026 07:30:00 am
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsApril 15, 2026 04:01:00 pm
Traws Pharma Reports Full Year 2025 Results and Provides Business HighlightsTRAW Stock Data
$15,422,373
6,872,146
2.64%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
Newtown
